Lost Money on CorMedix Inc. (CRMD)? Contact Levi & Korsinsky About Fraud Investigation

Core Viewpoint - CorMedix Inc. is under investigation for potential violations of federal securities laws following a significant revenue guidance reduction due to changes in reimbursement policy for its product DefenCath [1][2]. Financial Performance - CorMedix announced preliminary fourth quarter and full year 2025 results, revealing a revenue guidance cut from $400 million to a range of $300 million to $320 million [2]. - The anticipated reimbursement policy change for DefenCath is expected to significantly reduce institutional reimbursement levels and net pricing in the second half of 2026 [2]. Market Reaction - Following the announcement of the revenue guidance reduction, CorMedix's stock price fell over 21%, opening at $8.73 per share [2].